Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Core Viewpoint - Clearmind Medicine Inc. announced positive safety topline results from the second cohort of its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][5]. Group 1: Clinical Trial Results - The second cohort of the trial involved six additional patients and confirmed the safety and tolerability profile established in the first cohort [2][3]. - No serious adverse events were reported, reinforcing the positive safety profile of CMND-100 [3][5]. - The trial is a multinational study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD [4]. Group 2: Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health issues, including AUD [1][6]. - The company holds a portfolio of nineteen patent families, with 31 granted patents, and aims to expand its intellectual property [7].